Language: Français

Heparin Induced Thrombocytopenia

 Heparin Induced Thrombocytopenia (9892-08) Discuss the antibody implicated in Heparin Induced Thrombocytopenia (HIT), along with clinical findings and laboratory assays. This course covers the clinical features, mechanism, detection methods and treatment of HIT including a short historical perspective and review of heparin. Version Date: December 2008

Code 9892-08
Level Advanced

Member Price


Non-Member Price



Additional Details

PEP hours: 16
CPS credits: 1.1
Level: Advanced
Course Type: Express
Start Date: Upon registration
Completion: Up to 52 weeks
Delivery: PDF via email
Prerequisites: None
Textbook: N/A
Equipment: Computer with Internet is required
Learning Outcomes:
  • Describe the mode of action, clinical response and monitoring of unfractionated heparin.
  • Contrast and compare low molecular weight heparin with unfractionated heparin.
  • Describe briefly the early historical discoveries that have lead to the current knowledge of HIT.
  • Explain the nature of the antigen that causes production of HIT antibodies.
  • Discuss the steps involved when HIT antibodies cause platelet activation.
  • Explain the timeline of HIT.
  • Describe the transient nature of HIT antibodies.
  • Briefly outline differences in HIT positivitiy between various patient groups.
  • Discuss the morbidity and mortality of patients affected with HIT.
  • Recognize common nomenclature used to describe HIT in the literature.
  • List clinical symptoms of HIT.
  • Discuss the variability in platelet ‘alert’ values for suspect HIT cases.
  • Briefly discuss the thrombosis risk in a HIT positive patient.
  • List other complications that may alert medical staff to a positive HIT patient.
  • Briefly describe the methodology used for various HIT assays.
  • List the pros and cons of each assay type.
  • Explain the difference between HIT and non-immune thrombocytopenia.
  • Discuss the possible mechanisms that cause delayed-reaction HIT.
  • List alternative anticoagulants suitable for HIT positive patients.
  • List treatment options that should avoided in HIT patients.
Author/Instructor: Linda Stang, MLT
Version Date: December 2008